Drug Development Pipeline
Inhaled aztreonam (Cayston®) is an antibiotic that has been approved for people with CF who are chronically infected with Pseudomonas aeruginosa.
A Phase 3 clinical trial demonstrated improvement in lung function and respiratory symptoms for those infected with Pseudomonas aeruginosa. Cayston® received FDA approval in 2010.
The program was sponsored by Gilead Sciences, Inc. and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Aztreonam (Cayston®) Studies
Latest News on Aztreonam
November 15, 2010
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
March 04, 2010
A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
February 22, 2010
The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis (CF).
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More